Michael D. Keller
George Washington University
Publications 83
#1Adam S. Nelson (Cincinnati Children's Hospital Medical Center)H-Index: 8
#2Teri Clark (Cincinnati Children's Hospital Medical Center)
Last.Michael D. KellerH-Index: 12
view all 14 authors...
Introduction Recipients of solid organ transplant (SOT) are at risk of viral infection and development of viral-driven malignancy (EBV-PTLD) due to immunosuppressive medications to prevent organ rejection. Treatments are limited by poor efficacy and organ toxicity, and reduction in immunosuppression to enable the patient's immune system fight the infection risks organ rejection. Allogeneic viral specific T-cells (VST) have been used to treat viral infections after stem cell transplant, and here ...
Introduction Adenoviral (AdV) infections are common after HSCT and are a major cause of complications. Antiviral medications are frequently ineffective and toxic. At CCHMC, viral specific T cells (VST) from 3rd party donors are generated by pulsing peripheral blood mononuclear cells (PBMCs) with viral peptide pools (pepmix). The choice of VST product for each patient is based on pre-clinical evidence of anti-AdV activity and the degree of HLA match as the viral epitopes and HLA restriction drivi...
#1Shabnum Patel (GW: George Washington University)H-Index: 7
#2Ryo HanajiriH-Index: 5
Last.Catherine M. Bollard (GW: George Washington University)H-Index: 46
view all 12 authors...
Abstract While anti-retroviral therapy (ART) is successful in suppressing HIV-1 replication, HIV latently infected reservoirs are not eliminated, representing a major hurdle in efforts to eradicate the virus. Current strategies to eradicate HIV involve two steps: (1) the reactivation of latently infected cells with latency reversing agents (LRAs) to expose persisting HIV and (2) the elimination of these cells with immune effectors while continuing ART to prevent reinfection. HIV-specific T cells...
#1Michael D. KellerH-Index: 12
#2Patrick J. HanleyH-Index: 18
Last.Troy C. Quigg (Boston Children's Hospital)H-Index: 4
view all 23 authors...
Background Adoptive immunotherapy using banked virus-specific T-lymphocytes (VSTs) derived from partially HLA-matched donors has been successful in restoring antiviral immunity after hematopoietic stem cell transplantation (HSCT), although broad availability of this therapy is currently limited, and best methods for donor-recipient matching remain unclear. Objective To determine the feasibility and efficacy of third-party VSTs for the treatment of immunocompromised pediatric patients with refrac...
#1Ivan K. Chinn (BCM: Baylor College of Medicine)H-Index: 13
#2Alice Y. Chan (UCSF: University of California, San Francisco)H-Index: 11
Last.Jolan E. Walter (USFSP: University of South Florida St. Petersburg)H-Index: 20
view all 24 authors...
Abstract Genetic testing has become an integral component of the diagnostic evaluation of patients with suspected primary immunodeficiency diseases. Results of genetic testing can have profound impact on clinical management decisions. Clinical providers must therefore demonstrate proficiency in interpreting genetic data. Because of the need for increased knowledge regarding this practice, the American Academy of Allergy, Asthma, and Immunology Primary Immunodeficiency Diseases Committee establis...
#1Katherine Harris (Children's National Medical Center)H-Index: 2
#2Michael D. Keller (Children's National Medical Center)H-Index: 12
Last.Gelina M. Sani (Children's National Medical Center)H-Index: 1
view all 6 authors...
#1Michael D. KellerH-Index: 12
#2Sam Darko (NIH: National Institutes of Health)H-Index: 11
Last.Catherine M. BollardH-Index: 46
view all 15 authors...
1 CitationsSource
#1Hye Kyung Lim (Rockefeller University)H-Index: 4
#2Sarah X.L. Huang (University of Texas Health Science Center at San Antonio)H-Index: 8
Last.Shen-Ying Zhang (Rockefeller University)H-Index: 37
view all 32 authors...
2 CitationsSource
#1Ryo HanajiriH-Index: 5
#2Gelina M. SaniH-Index: 1
Last.Catherine M. Bollard (GW: George Washington University)H-Index: 46
view all 7 authors...
Abstract Background Zika virus (ZIKV) infection can cause severe birth defects in newborns with no effective currently available treatment. Adoptive transfer of virus-specific T cells has proven to be safe and effective for the prevention or treatment of many viral infections, and could represent a novel treatment approach for patients with ZIKV infection. However, extending this strategy to the ZIKV setting has been hampered by limited data on immunogenic T-cell antigens within ZIKV. Hence, we ...